Peer-reviewed veterinary case report
The role of rituximab in the treatment of canine lymphoma: an ex vivo evaluation.
- Journal:
- Veterinary journal (London, England : 1997)
- Year:
- 2006
- Authors:
- Impellizeri, Joseph A et al.
- Affiliation:
- Sacramento Animal Medical Group · United States
- Species:
- dog
Abstract
Targeting the CD20 receptor that is common to many B-cell Non-Hodgkin's Lymphoma subtypes in people, rituximab is a chimeric monoclonal antibody which has significantly improved disease-free survival rates compared with the use of cytotoxic agents alone. This study evaluated ex vivo canine B cell binding and depletion by rituximab with flow cytometric technique as possible proof of concept for treatment of canine lymphoma. Despite immunohistochemistry supporting CD20 expression, rituximab did not bind or deplete canine B cells and it is unlikely that it will be added to the armamentarium of treatment options for canine lymphoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication: https://pubmed.ncbi.nlm.nih.gov/16624725/